Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus

Aliment Pharmacol Ther. 2005 Apr 15;21(8):969-75. doi: 10.1111/j.1365-2036.2005.02406.x.

Abstract

Background: Proton-pump inhibitors are effective at preventing the acid component of gastro-oesophageal refluxate from entering the oesophagus. It is not clear whether proton-pump inhibitors prevent duodenogastro-oesophageal reflux.

Aim: To measure oesophageal exposure to duodenogastro-oesophageal refluxate while on proton-pump inhibitors in patients with Barrett's oesophagus.

Methods: Twenty-five patients (23 male) with Barrett's oesophagus underwent 24 h oesophageal pH and Bilitec 2000 monitoring while on omeprazole 40 mg/day (n = 19) or omeprazole 60 mg/day (n = 6). All patients were undergoing argon plasma ablation of their Barrett's epithelium as part of a clinical trial and the Bilitec measurements were only carried out after the ablation had been completed.

Results: 20 of 25 (80%) patients had a normal oesophageal pH profile. Fifteen of the 25 (60%) had abnormal oesophageal exposure to bile as measured by Bilitec 2000. Of the 20 patients who had a normal 24 h oesophageal pH profile, 11 (55%) had pathological exposure to bile in their oesophagus.

Conclusion: Complete acid suppression does not guarantee elimination of duodenogastro-oesophageal reflux.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Ulcer Agents / therapeutic use*
  • Barrett Esophagus / complications*
  • Duodenal Diseases / drug therapy*
  • Esophagoscopy
  • Esophagus / physiology
  • Female
  • Gastric Acid / physiology*
  • Gastroesophageal Reflux / complications
  • Gastroesophageal Reflux / prevention & control*
  • Humans
  • Hydrogen-Ion Concentration
  • Male
  • Middle Aged
  • Omeprazole / therapeutic use*
  • Proton Pump Inhibitors

Substances

  • Anti-Ulcer Agents
  • Proton Pump Inhibitors
  • Omeprazole